Guidelines for the Pharmacotherapy of Schizophrenia in Adults

The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains. Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations ex...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of psychiatry Vol. 62; no. 9; p. 604
Main Authors: Remington, Gary, Addington, Donald, Honer, William, Ismail, Zahinoor, Raedler, Thomas, Teehan, Michael
Format: Journal Article
Language:English
Published: United States 01.09.2017
Subjects:
Adult
Antipsychotic Agents - therapeutic use
Canada
Evidence-Based Medicine - standards
Humans
Practice Guidelines as Topic - standards
Schizophrenia - drug therapy
antipsychotics
clinical practice guideline
adult psychiatry
schizophrenia
systematic review
pharmacotherapy
ISSN:1497-0015, 1497-0015
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains. Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline. Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines. In most cases, evidence-based recommendations are made that can be used to guide current clinical treatment and decision making. Notably, however, there is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
ISSN:1497-0015
1497-0015
DOI:10.1177/0706743717720448